Alkeon Capital Management
DNTH icon

Alkeon Capital Management’s Dianthus Therapeutics DNTH Stock Holding History

Alkeon Capital Management’s Portfolio DNTH Stock Details DNTH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q3 		– Sell
-37,500
Closed -$4.51M – 151
2020
Q2 		$4.51M Hold
37,500
– – 0.01% 133
2020
Q1 		$3.77M Hold
37,500
– – 0.02% 122
2019
Q4 		$9.1M Buy
37,500
+6,250
+20% +$1.17M 0.03% 109
2019
Q3 		$5.13M Buy
31,250
+6,250
+25% +$1.19M 0.02% 120
2019
Q2 		$5.9M Buy
+25,000
New +$6.18M 0.02% 120
2018
Q3 		– Sell
-4,250
Closed -$918K – 131
2018
Q2 		$918K Buy
+4,250
New +$959K ﹤0.01% 121

Other funds holding DNTH

TGI
TRV GP IV Boston, Massachusetts $254M AUM 426.76% 1-Year Est. Return
GGHC
Gilder Gagnon Howe & Co New York $9.69B AUM 55.7% 1-Year Est. Return
CC
Casdin Capital New York $2B AUM 147.21% 1-Year Est. Return
AI
Alphabet Inc Mountain View, California $99.1B AUM 124.46% 1-Year Est. Return
EAM
Eventide Asset Management Boston, Massachusetts $7.48B AUM 104.76% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
ACM
Aquilo Capital Management San Francisco, California $55.8M AUM 41.76% 1-Year Est. Return
UBS AM
UBS AM Chicago, Illinois $550B AUM 43.33% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Alkeon Capital Management's DNTH Position: Q3 2020 in Review

Alkeon Capital Management sold out of Dianthus Therapeutics (DNTH) in Q3 2020, closing a stake of 37,500 shares — an estimated $4.51M sold.

Alkeon Capital Management first reported a position in DNTH in Q2 2018 and held it in 6 quarters. The position peaked at $9.1M in Q4 2019. 94 funds tracked by Wall St. Rank hold DNTH as of Q3 2020.

  • Alkeon Capital Management reported no remaining Dianthus Therapeutics position as of Q3 2020 after selling out during the quarter.
  • Alkeon Capital Management sold 37,500 Dianthus Therapeutics shares in Q3 2020, an estimated $4.51M.
  • Alkeon Capital Management first reported a position in Dianthus Therapeutics in Q2 2018 and held it in 6 quarters.
  • Alkeon Capital Management's Dianthus Therapeutics position peaked at $9.1M in Q4 2019.
  • 94 funds tracked by Wall St. Rank held Dianthus Therapeutics as of Q3 2020.

Based on Alkeon Capital Management's 13F filing for Q3 2020, filed 16 Nov 2020.